NASDAQ:DSGN Design Therapeutics (DSGN) Stock Forecast, Price & News $5.59 -0.33 (-5.57%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$5.45▼$5.9150-Day Range$4.99▼$7.6452-Week Range$4.90▼$26.30Volume99,136 shsAverage Volume165,885 shsMarket Capitalization$312.76 millionP/E RatioN/ADividend YieldN/APrice Target$17.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Design Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside217.5% Upside$17.75 Price TargetShort InterestBearish23.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.66) to ($2.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector762nd out of 985 stocksPharmaceutical Preparations Industry372nd out of 484 stocks 3.4 Analyst's Opinion Consensus RatingDesign Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.75, Design Therapeutics has a forecasted upside of 217.5% from its current price of $5.59.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.00% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 19.1, which indicates bearish sentiment.Change versus previous monthShort interest in Design Therapeutics has recently increased by 35.51%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSGN. Previous Next N/A News and Social Media Coverage Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.80% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.73% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.66) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Design Therapeutics (NASDAQ:DSGN) StockDesign Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Read More Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DSGN Stock News HeadlinesMay 31, 2023 | finance.yahoo.comDesign Therapeutics to Present at the 2023 Jefferies Healthcare ConferenceMay 19, 2023 | americanbankingnews.comContrasting Athersys (NASDAQ:ATHX) and Design Therapeutics (NASDAQ:DSGN)June 9, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 18, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Design Therapeutics (DSGN)May 14, 2023 | americanbankingnews.comFY2023 EPS Estimates for Design Therapeutics, Inc. (NASDAQ:DSGN) Boosted by WedbushMay 12, 2023 | msn.comWedbush Maintains Design Therapeutics (DSGN) Outperform RecommendationMay 12, 2023 | marketwatch.comTypes of Applications Driving Digital Therapeutics Market Growth: An OverviewMay 12, 2023 | msn.comRBC Capital Maintains Design Therapeutics (DSGN) Outperform RecommendationJune 9, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 10, 2023 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Design Therapeutics (DSGN)May 10, 2023 | finanznachrichten.deDesign Therapeutics, Inc.: Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comDesign Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial ResultsMay 9, 2023 | marketwatch.comSynCrest Launches CRDMO Service for Peptide-based TherapeuticsMay 4, 2023 | msn.comGoldman Sachs Upgrades Design Therapeutics (DSGN)May 4, 2023 | americanbankingnews.comDesign Therapeutics (NASDAQ:DSGN) Lifted to "Neutral" at The Goldman Sachs GroupMay 4, 2023 | markets.businessinsider.comDesign Therapeutics (DSGN) was upgraded to a Hold Rating at Goldman SachsMay 1, 2023 | markets.businessinsider.comCognition Therapeutics Appoints John Doyle As Chief Financial OfficerApril 24, 2023 | finance.yahoo.comDesign Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023April 11, 2023 | investorplace.comWhy Design Therapeutics (DSGN) Stock Is Going Nowhere But DownMarch 23, 2023 | americanbankingnews.comAnalyzing Sensei Biotherapeutics (NASDAQ:SNSE) & Design Therapeutics (NASDAQ:DSGN)March 16, 2023 | finanznachrichten.deDesign Therapeutics, Inc.: Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 15, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Design Therapeutics (DSGN)March 14, 2023 | msn.comDesign Therapeutics GAAP EPS of -$0.31 beats by $0.03March 14, 2023 | finance.yahoo.comDesign Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 8, 2023 | finance.yahoo.comDesign Therapeutics to Participate in the SVB Securities Virtual Global Biopharma ConferenceDecember 29, 2022 | benzinga.comSHAREHOLDER ALERT: Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Announces Investigation of Design Therapeutics, Inc. (DSGN)December 14, 2022 | finance.yahoo.comIndependent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN)See More Headlines DSGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSGN Company Calendar Last Earnings3/14/2023Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DSGN CUSIPN/A CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.75 High Stock Price Forecast$24.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+217.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.73% Return on Assets-19.98% Debt Debt-to-Equity RatioN/A Current Ratio35.25 Quick Ratio35.25 Sales & Book Value Annual Sales$230,000.00 Price / Sales1,359.83 Cash FlowN/A Price / Cash FlowN/A Book Value$5.85 per share Price / Book0.96Miscellaneous Outstanding Shares55,950,000Free Float40,393,000Market Cap$312.76 million OptionableNot Optionable Beta1.21 Key ExecutivesDr. João Siffert M.D. (Age 60)Pres, CEO & Director Comp: $993kDr. Sean Jeffries Ph.D. (Age 43)Chief Operating Officer Comp: $476kDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerDr. Elizabeth Gordon Ph.D.Sr. VP of Regulatory AffairsDr. Jae B. Kim FACC (Age 53)M.D., Chief Medical Officer Ms. Dawn GiangiulioControllerMore ExecutivesKey CompetitorsAtai Life SciencesNASDAQ:ATAITango TherapeuticsNASDAQ:TNGXMacroGenicsNASDAQ:MGNXReneo PharmaceuticalsNASDAQ:RPHMPrecigenNASDAQ:PGENView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 6,156 shares on 5/18/2023Ownership: 0.046%New York State Common Retirement FundSold 6,832 shares on 5/18/2023Ownership: 0.032%Geode Capital Management LLCBought 29,995 shares on 5/16/2023Ownership: 1.131%Baker BROS. Advisors LPSold 65,247 shares on 5/16/2023Ownership: 1.121%Squarepoint Ops LLCBought 109,214 shares on 5/16/2023Ownership: 0.195%View All Insider TransactionsView All Institutional Transactions DSGN Stock - Frequently Asked Questions Should I buy or sell Design Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DSGN shares. View DSGN analyst ratings or view top-rated stocks. What is Design Therapeutics' stock price forecast for 2023? 4 Wall Street research analysts have issued 12-month target prices for Design Therapeutics' shares. Their DSGN share price forecasts range from $6.00 to $24.00. On average, they anticipate the company's stock price to reach $17.75 in the next twelve months. This suggests a possible upside of 217.5% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. How have DSGN shares performed in 2023? Design Therapeutics' stock was trading at $10.26 at the beginning of 2023. Since then, DSGN shares have decreased by 45.5% and is now trading at $5.59. View the best growth stocks for 2023 here. Are investors shorting Design Therapeutics? Design Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 7,480,000 shares, an increase of 35.5% from the April 30th total of 5,520,000 shares. Based on an average daily trading volume, of 391,100 shares, the days-to-cover ratio is presently 19.1 days. Approximately 23.0% of the shares of the stock are short sold. View Design Therapeutics' Short Interest. When is Design Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our DSGN earnings forecast. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings data on Tuesday, March, 14th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.03. What ETFs hold Design Therapeutics' stock? ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Neuroscience and Healthcare ETF (IBRN), Principal Healthcare Innovators ETF (BTEC) and BlackRock Future Health ETF (BMED) and When did Design Therapeutics IPO? (DSGN) raised $228 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. What is Design Therapeutics' stock symbol? Design Therapeutics trades on the NASDAQ under the ticker symbol "DSGN." Who are Design Therapeutics' major shareholders? Design Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (6.26%), BlackRock Inc. (5.69%), FMR LLC (1.71%), Principal Financial Group Inc. (1.29%), State Street Corp (1.27%) and Geode Capital Management LLC (1.13%). Insiders that own company stock include Arsani William, Joao Md Siffert, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Design Therapeutics' stock price today? One share of DSGN stock can currently be purchased for approximately $5.59. How much money does Design Therapeutics make? Design Therapeutics (NASDAQ:DSGN) has a market capitalization of $312.76 million and generates $230,000.00 in revenue each year. The company earns $-63,310,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. How can I contact Design Therapeutics? Design Therapeutics' mailing address is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. The official website for the company is www.designtx.com. The company can be reached via phone at 858-293-4900 or via email at alicia@thrustsc.com. This page (NASDAQ:DSGN) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.